Search results for "Liver function"

showing 10 items of 176 documents

Laparoscopic Microwave Thermal Ablation for the Treatment of Hepatocellular Carcinoma in Chronic Hepatic Patients

2020

Background: Laparoscopic microwave thermal ablation (LMWTA) is a well-established alternative treatment to liver resection for treatment of liver tumors. The aim of this study was to describe our experience in LMWTA for hepatocellular carcinoma (HCC) in chronic hepatic patients. Materials and Methods: A study group of 61 consecutive HCC patients treated with LMWTA from January, 2013 to May, 2020 were considered for this study. Patient characteristics, liver function test, operational characteristics, and complications were recorded. Results: Of the 61 patients who underwent LMWTA, median age was 64 (interquartile range [IQR]: 58-71) years, mean body mass index was 26.2 (IQR: 23.2-29.4); 44 …

Liver CirrhosisMaleLaparoscopic surgerymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentHepatitis C virusmedicine.disease_causeGastroenterologyLiver diseasePregnancymicrowave thermoablationInterquartile rangeInternal medicinemedicineHepatectomyHumansRisk factorMicrowavesAgedmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHyperthermia Inducedhepatocellular carcinomaHepatitis C ChronicMiddle Agedmedicine.diseaselaparoscopic surgerySurgeryHepatocellular carcinomaCatheter AblationFemaleLaparoscopySurgeryLiver function testsbusinessBody mass indexJournal of Laparoendoscopic & Advanced Surgical Techniques
researchProduct

Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.

2012

Background and Aims: Serum levels of γ-glutamyl-transpeptidase(γ-GT) were associated with liver disease severity and metabolic alterations, which in turn are able to affect hepatic damage. In patients with nonalcoholic fatty liver disease (NAFLD), genotype 1 chronic hepatitis C (G1CHC) and chronic hepatitis B (CHB), we assessed the link between liver fibrosis and γ-GT serum levels, and we evaluated if normal or high γ-GT serum levels affect the association between insulin resistance (IR) and severity of liver fibrosis. Methods: 843 consecutive patients with chronic liver disease (CLD)(193 NAFLD, 481 G1CHC, 169 CHB) were evaluated by liver biopsy (Kleiner and Scheuer scores) and clinical and…

Liver CirrhosisMalePathologylcsh:MedicineNonalcoholic SteatohepatitisChronic liver diseaseBiochemistryGastroenterologyCohort StudiesLiver diseaseEndocrinologyRisk FactorsFibrosisNonalcoholic fatty liver diseaseInsulinGamma-glutamyltransferaselcsh:ScienceSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testbiologyEnzyme ClassesLiver DiseasesFatty livergamma glutamyl transferase liver fibrosis insulin resistancegamma-GlutamyltransferaseMiddle AgedEnzymesLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignGastroenterology and HepatologySettore MED/08 - Anatomia PatologicaTransferasesInternal medicinemedicineHumansStatistical MethodsBiologyDemographyEndocrine PhysiologyInfectious Hepatitisbusiness.industrylcsh:Rmedicine.diseaseChronic DiseaseMultivariate Analysisbiology.proteinlcsh:QInsulin ResistanceLiver function testsbusinessPLoS ONE
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model.

2000

OBJECTIVE: Percutaneous ethanol injection may prolong the survival of patients with small hepatocellular carcinoma associated with cirrhosis. The aim was to identify prognostic factors of survival and of local recurrence, as well as separate new lesions. METHODS: We performed Cox regression analysis in 115 consecutive patients with hepatocellular carcinoma (81 Child-Pugh class A, 34 Child-Pugh class B) treated by percutaneous ethanol injection. The validity of the model was tested by comparing predicted and observed survival in 105 independent patients from an external series. RESULTS: Overall survival rates were 89%, 63%, and 43% at 1, 2, and 3 yr, respectively. The 1-, 2-, and 3-yr surviv…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInjections IntralesionalSmall-cell carcinomaGastroenterologyLiver Function TestsInternal medicinemedicineCarcinomaHumansSurvival rateSerum AlbuminAgedHepatologymedicine.diagnostic_testEthanolbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateHepatocellular carcinomaFemalePercutaneous ethanol injectionbusinessLiver function testsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.

2015

Evidence has shown that indoxyl sulfate (IS) and p-cresyl sulfate (PCS) may be alternative predictors of clinical outcomes in chronic kidney disease (CKD). Both toxins are derived from the gastrointestinal tract and metabolised in the liver. However, it is unclear whether the liver affects the production of IS and PCS. Here, we explore the association between IS and PCS levels in liver cirrhosis and a CKD-based cohort (N = 115). Liver and kidney function was assessed and classified by a Child-Pugh score (child A–C) and a modified version of the Modification of Diet in Renal Disease (MDRD) equation (Stages 1–4), respectively. An animal model was also used to confirm the two toxin levels in a…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisColonlcsh:MedicineUrineSulfuric Acid EstersKidneyGastroenterologyCohort StudiesRats Sprague-DawleyCresolsInternal medicinemedicineAnimalsHumansRenal Insufficiency Chroniclcsh:ScienceAgedUremiaKidneyGastrointestinal tractMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RKidney metabolismMiddle Agedmedicine.diseaseUremiahumanitiesRatsGastrointestinal TractDisease Models Animalmedicine.anatomical_structureEndocrinologyTreatment OutcomeLiverMultivariate AnalysisLinear Modelslcsh:QFemaleLiver function testsbusinessIndicanKidney diseaseResearch ArticlePloS one
researchProduct

Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats

2020

BACKGROUND AND AIMS Portal hypertension is the main consequence of cirrhosis, responsible for the complications defining clinical decompensation. The only cure for decompensated cirrhosis is liver transplantation, but it is a limited resource and opens the possibility of regenerative therapy. We investigated the potential of primary human amniotic membrane-derived mesenchymal stromal (hAMSCs) and epithelial (hAECs) stem cells for the treatment of portal hypertension and decompensated cirrhosis. METHODS In vitro: Primary liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs) from cirrhotic rats (chronic CCl4 inhalation) were co-cultured with hAMSCs, hAECs or vehicle for…

Liver CirrhosisPathologymedicine.medical_specialtyhAECCirrhosisplacentaPortal venous pressure03 medical and health sciences0302 clinical medicineHypertension PortalSettore BIO/13 - BIOLOGIA APPLICATAAnimalsHumansMedicineAmnion610 Medicine & healthHepatologymedicine.diagnostic_testbusiness.industryMicrocirculationStem Cellschronic liver diseaseportal hypertensionEndothelial CellsAmniotic stem cellsmedicine.diseaseRatsLiver030220 oncology & carcinogenesisHepatic stellate cellPortal hypertensionVascular Resistance030211 gastroenterology & hepatologyStem cellbusinessHepatic fibrosisLiver function testshAMSCLiver International
researchProduct

Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases.

1998

SUMMARYComplement receptor type 1 (CR1) is an integral membrane protein of many haematopoietic cells and plays an important role in the clearance of complement-associated immune complexes, favouring their transport to liver and spleen macrophages. A small amount of soluble CR1 (sCR1) is also found in plasma and might originate directly from release of leucocytes and other circulating cells. In previous studies, an increase in serum sCR1 level has been observed in liver cirrhosis and end-stage renal failure. High levels have also been found in patients with some haematologic malignancies. sCR1 serum levels were measured using a specific double sandwich ELISA assay. The present study demonstr…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularImmunologyChronic liver diseaseLiver diseaseImmune systemInternal medicinemedicineImmunology and AllergyHumansmedicine.diagnostic_testbusiness.industryLiver Diseasesmedicine.diseaseHepatitis CImmune complexReceptors ComplementEndocrinologyHepatocellular carcinomaImmunologyChronic DiseaseOriginal ArticleLiver functionLiver function testsbusinessClinical and experimental immunology
researchProduct

Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?

2018

Direct acting antivirals stabilize or improve liver function in the majority of patients with hepatitis C virus cirrhosis. Hepatic decompensation is the main driver of death of patients with early, successfully treated hepatocellular carcinoma superimposed to cirrhosis. Treatment with direct acting antivirals could improve the prognosis of these subjects, independently from the subsequent course of hepatocellular carcinoma, if the efficacy in obtaining viral clearance is as high as in patients without a history of hepatocellular carcinoma, and if the risk of hepatocellular carcinoma recurrence is unaffected. When dealing with hepatocellular carcinoma patients, direct acting antivirals can b…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentHepacivirusLiver transplantationGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansHCCHepatologybusiness.industryLiver NeoplasmsCancerHepatitis CHepatitis C Chronicmedicine.diseasedigestive system diseasesLiver Transplantation030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyLiver functionNeoplasm Recurrence LocalViral hepatitisbusinessLiver cancerLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

2019

Background & Aims: In patients with hepatitis C virus (HCV)-related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis. Methods: Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N = 22, 44%) or previous decompensation …

Liver Cirrhosismedicine.medical_specialtyCirrhosisSofosbuvirHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsGastroenterologyInternal medicineHumansMedicineDecompensationAminopyrineChildCIRRHOSISHepatic encephalopathyaminopyrine breath testBreath testHepatologymedicine.diagnostic_testdirect antiviral agentCumulative dosebusiness.industryHepatitis C Chronicmedicine.diseaseHepatitis CBreath Testsliver functionLiver functionbusinessDIRECT ANTIVIRAL AGENTSAMINOPYRINE BREATH TEST; CIRRHOSIS; DIRECT ANTIVIRAL AGENTS; LIVER FUNCTIONmedicine.drugcirrhosi
researchProduct

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

2022

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. Thes…

Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessHepatology
researchProduct